Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome ...Middle East

The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy...

Read More Details
Finally We wish PressBee provided you with enough information of ( Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome )

Also on site :

• 'The Young and the Restless' Heartthrob, 48, Makes Rare Appearance with Daughter
• NYT Connections Sports Edition Today: Hints and Answers for June 19
• Iranians mostly lost internet access on the sixth day of Israeli strikes.